Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
2009
Yazbek, R. | Howarth, G. | Abbott, C.
Copyright © 2009 Elsevier Ltd. All rights reserved. Data source: Figures & tables, https://doi.org/10.1016/j.tips.2009.08.003
Afficher plus [+] Moins [-]Dipeptidyl peptidase (DPP)-4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T-cell proliferation and cytokine production, leading to their investigation in numerous pre-clinical models of inflammatory diseases, including arthritis, multiple sclerosis and inflammatory bowel disease. Recent data suggest that the early DPP4- specific inhibitors might also bind DPP8 and DPP9, thus exerting their effects through non-specific binding. This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease.
Afficher plus [+] Moins [-]Roger Yazbeck, Gordon S. Howarth and Catherine A. Abbott
Afficher plus [+] Moins [-]Informations bibliographiques
Cette notice bibliographique a été fournie par University of Adelaide
Découvrez la collection de ce fournisseur de données dans AGRIS